Compare Apartment Investment and Management Co (AIV) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs Novo Nordisk A/S — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Novo Nordisk A/S trades at $46.26 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 552.6× Apartment Investment and Management Co's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.
| AIV | NVO | |
|---|---|---|
Market Cap | $376.16M | $207.85B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $63.98 |
52-Week Low | $2.59 | $35.29 |
Enterprise Value | $738.32M | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.62, down 1.5% recently, with a bearish technical signal from moving averages. The company reported Q4 2025 EPS of $1.06, beating expectations, but revenue declined to $138.49M in 2025. Valuation ratios show a low P/B of 0.76, suggesting potential undervaluation, while a net income margin of 400.05% reflects significant one-time tax benefits. Cash flow improved with a net inflow of $234M in 2025.
Outlook is mixed: strong profitability metrics and a scheduled dividend in 2026 offer upside, but inconsistent earnings history and revenue volatility pose risks. Analyst consensus is cautious with 33% buy ratings. Investors should weigh the attractive valuation against operational challenges in the real estate sector.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
